Colorado capped a drug's price. A federal judge voided it before it took effect.

Colorado created its Prescription Drug Affordability Board (PDAB) in 2021, under Senate Bill 21-175, giving it a power no other state board had yet used: after finding a drug "unaffordable," it can set an Upper Payment Limit (UPL) — a ceiling on what insurers and patients in Colorado may pay for it.▸ On October 3, 2025, after four years of review, the board used that power for the first time, voting to cap the price of Enbrel (etanercept), a biologic used for rheumatoid arthritis and other autoimmune conditions, at $600 per 50-milligram dose. Colorado became the first state in the country to actually impose a price cap on a prescription drug. Nine months later, on July 2, 2026, a federal judge blocked the rule before it ever took effect.

Enbrel doesn't have one price — it has a ladder of them, depending on who's buying.▸ The Colorado PDAB's own benchmarking analysis lines them up: the price the federal government uses to track drug costs nationally, the price Colorado tracks separately, the price federal agencies pay under a supply schedule, the discounted price available to the VA and other federal health programs, and — near the bottom — the price the board decided a patented biologic should actually cost. The board didn't invent that number. It started from Medicare's "maximum fair price" for Enbrel, $30,356 a year — itself a price set through a separate federal negotiation — and rounded up to the nearest hundred dollars per weekly dose, landing on $600, which Colorado Sun calculated comes out to roughly $31,000 a year at the standard once-weekly adult dosing schedule.

The gap between the top and bottom of that ladder is the whole argument for the board's existence: the price tracked nationally is more than three times the price the board decided Coloradans should pay.▸ The gap between the new ceiling and what Colorado actually pays today is the argument for why regulators bothered.

Before any cap takes effect, Colorado's All Payer Claims Database shows where a year of Enbrel actually goes for the roughly 2,585 Coloradans who filled a prescription for it in 2022 — about 60% of them privately insured, per Colorado Sun's reporting on the board's patient count.▸ Insurance plans absorb most of the cost; patients carry a smaller, but real, share in deductibles, coinsurance, and copays.

That $4,639 average out-of-pocket figure doesn't include premiums, and it's an average — 71% of the patients surveyed by the board (out of a 38-response sample the board itself flagged as thin) said Enbrel's price made it difficult to access.▸ One Colorado patient wrote to the board that "neither the board nor any of its experts can say unequivocally that fixing the price would lead to reduced out-of-pocket costs for individual patients" — a reminder that a UPL caps what plans and patients may be charged, not what any individual patient's bill turns out to be once a plan's own cost-sharing design is applied.

Amgen sued twice.▸ The first suit, filed in March 2024 before any UPL existed, was dismissed for lack of standing. The second, Amgen Inc. et al. v. Mizner et al. (Case No. 1:25-cv-3452, D. Colo.), came on October 30, 2025 — three weeks after the board actually set the $600 price — naming Colorado's insurance commissioner and the PDAB's members as defendants. On July 2, 2026, Chief Judge Daniel D. Domenico granted Amgen's request for a preliminary injunction, blocking the rule before its January 1, 2027 effective date. His reasoning rested on a prior federal appeals ruling against a similar District of Columbia drug-pricing law: "Since under binding Federal Circuit precedent, caps on the price of patented drugs like Enbrel are preempted by federal law, Amgen's motion must be granted," he wrote, adding that "Colorado's attempt to rebalance Congress's patent system is preempted by federal law." The state had argued Amgen couldn't show real harm, since other links in the supply chain might absorb a price cut — Domenico called that argument "convoluted, confusing, and often counterintuitive" as a description of the drug-pricing system, but not a reason to deny the injunction, writing that "as a result of Colorado's cap, Amgen will receive less money from its wholesalers and will fare more poorly in negotiations with other purchasers in Colorado and elsewhere."

Reaction split along predictable lines.▸ Amgen said in a statement it "appreciate[s] the court's careful consideration and remain[s] confident in [its] position as the case moves forward." Adam Fox, deputy director of the Colorado Consumer Health Initiative, called the ruling "a step backwards for Colorado and consumers." Sophia Hennessy of the same group had said, when the cap was first adopted, that it "has the potential to save $32 million from drug spending" statewide — an advocacy estimate, not a figure the board itself published; the board's own cost-benefit analysis of the rule explicitly declined to quantify economic benefits, calling them "difficult to quantify" before a specific dollar figure was set.

The injunction blocks enforcement only "at least until Amgen's underlying lawsuit is resolved," per Colorado Sun's reporting on the order — it isn't a final ruling on the merits.▸ The Colorado PDAB was already reviewing two more drugs for UPLs, Stelara and Cosentyx; Stelara has since gone off-patent, but Cosentyx is still under patent, meaning Domenico's reasoning would likely block a UPL on it too if it reaches that stage. A spokesperson for the Colorado Division of Insurance, which oversees the board, declined to comment on the ruling, citing the pending litigation. Other states — Washington, Maryland, Oregon, Minnesota — have PDABs of their own in earlier stages; Colorado was the only one that had actually reached a price cap, and a federal judge has now told it, at least provisionally, that this specific tool doesn't survive contact with patent law.

Patient counts and payment averages are drawn from Colorado's All Payer Claims Database as compiled by the PDAB (2022 utilization, 2023 cost data); the $32 million statewide savings estimate is an advocacy group's projection, not a figure verified or published by the state.